Envafolimab (CD274/PD-L1/B7-H1) Antibody, Monoclonal | 10-964

Envafolimab (CD274/PD-L1/B7-H1) Antibody, Monoclonal | 10-964 | Gentaur UK, US & Europe Distribution

Host: N/A

Reactivity: N/A

Homology: N/A

Immunogen: Chimeric / CD274/PD-L1/B7-H1 [Homo sapiens]

Research Area: Drug Analogues

Tested Application: N/A

Application: N/A

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: >95%

Clonality: Monoclonal

Clone: N/A

Isotype: (VH-CH2-CH3) 2

Conjugate: Unconjugated

Physical State: N/A

Buffer: PBS buffer pH7.5

Concentration: N/A

Storage Condition: Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚C for 1-2 weeks. Store at -20 ˚C for 12 months. Store at -80 ˚C for long term storage.

Alternate Name: KN-035

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: Envafolimab (KN035) is the first humanized anti-PD-L1 single domain antibody and new fusion protein of human IgG1 Fc. Compared with the PD-1/PD-L1 antibody that is currently on the market and under development, it has obvious advantages. . Envafolimab has the advantages of subcutaneous injection, stability at room temperature, and rapid tumor penetration, thereby improving the compliance of cancer patients with medication and improving the quality of life of patients. It is in line with the future trend of long-term management of cancer as a chronic disease.